AMPCO-Pittsburgh Corporation delivered its strongest quarter in two years on August 11, 2026, with adjusted EBITDA, a non-GAAP measure that strips out interest, taxes, depreciation, amortization, and one-time items, of $9.8 million in Q2 2026 - up 22% from a year ago even as reported net sales fell 9% to $102.9 million, because the year-ago quarter still carried the now-shuttered U.K. cast roll business. The headline number matters less than the composition underneath it. Both operating segments posted higher adjusted operating income than a year ago despite the FCEP segment selling 13.6% less, and the company's order book expanded $39.9 million sequentially to a $385.4 million backlog, the highest reading in the recovery cycle. Net income attributable to Ampco swung to $1.5 million, or $0.07 per diluted share, from a $7.3 million loss a year ago, and free cash flow, defined as operating cash flow less capital spending, narrowed to a $5.5 million outflow from a $3.8 million outflow as the Sweden facility ramp absorbed spending that the 2025 quarter deferred.
The thesis we are writing into the tape is straightforward: the demand backdrop is turning, the operational restructuring is mostly behind the company, and the legacy U.K. drag no longer distorts the year-over-year comparisons from Q3 2026 forward. The remaining drag is balance-sheet - $130.5 million of net debt against $7.0 million of cash and $29.0 million of total liquidity - and the long-tail asbestos liability, which is the single reason a specialty steel and pumps manufacturer trades like a litigation vehicle rather than an industrial. If the steel cycle and the air-and-liquid processing end markets keep cooperating into the back half, the gap between a $195 million market capitalization and the underlying earnings power should narrow.
The single load-bearing risk is the asbestos liability revaluation: an additional charge against the $185 million carrying value of that obligation would compress book equity (currently $48.3 million, of which $17.2 million belongs to a noncontrolling interest) and could trigger a fresh round of solvency scrutiny. The falsifiable clock for the bull case is the Q3 2026 print, expected in early November, where the year-ago U.K. cast roll contribution falls out of the comparison and organic same-store growth becomes the read. If Q3 2026 adjusted EBITDA exceeds $12 million and the backlog holds above $400 million, the recovery thesis is intact; if either leg slips, the re-rating stalls.